STOCK TITAN

Idexx (IDXX) insider files Form 144 to sell 2,187 shares on Nasdaq

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Idexx Laboratories (IDXX) Form 144 notice: An insider intends to sell 2,187 shares of common stock, representing an aggregate market value of $1,415,700.21, on 08/22/2025 through Morgan Stanley Smith Barney LLC on NASDAQ. The shares were acquired the same day via stock option exercise and paid in cash. There were 80,004,694 shares outstanding reported for the issuer. The filer reports no sales in the prior three months. The filer certifies they are not aware of undisclosed material adverse information about the issuer.

Positive

  • Complete disclosure of broker, number of shares, aggregate value, acquisition method, and payment type
  • No sales in prior three months, suggesting this is not part of ongoing heavy insider selling
  • Securities were acquired by option exercise and paid in cash, indicating standard compensation monetization

Negative

  • None.

Insights

TL;DR: Insider plans to sell a small block of shares acquired by option exercise; transaction appears routine and non-recurring.

The notice shows an insider executed options and intends to sell 2,187 shares valued at $1,415,700.21 through a broker on the Nasdaq exchange. The shares were acquired and are to be sold on the same date and were paid for in cash, which is consistent with option exercise followed by an immediate disposition. No other sales were reported in the prior three months, suggesting this is not part of a recurring disposal pattern. As a percentage of the outstanding share count (80,004,694), the block is immaterial from a dilution or control standpoint. The filing contains the required representation that no undisclosed material adverse information exists.

TL;DR: Disclosure aligns with Rule 144 procedural requirements; transaction raises no immediate governance concerns.

The Form 144 provides the broker name, size, market value, acquisition method, and payment type, meeting standard disclosure elements. The simultaneous acquisition by exercise and planned sale may reflect routine option monetization. The absence of aggregated sales in the prior three months reduces concern about concentrated insider selling. The filing includes the signature representation about material information, which is standard and important for compliance.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 for IDXX disclose?

It discloses an intended sale of 2,187 common shares valued at $1,415,700.21 to be executed on 08/22/2025 via Morgan Stanley Smith Barney LLC on NASDAQ.

How were the shares acquired according to the filing?

The filing states the shares were acquired on 08/22/2025 by a stock option exercise and paid for in cash.

Does the Form 144 show other recent insider sales?

The filing reports Nothing to Report under securities sold during the past three months.

How large is the sale relative to outstanding shares?

The issuer reported 80,004,694 shares outstanding; the 2,187-share block is immaterial as a percentage of that total.

Which broker will handle the sale?

The broker named is Morgan Stanley Smith Barney LLC Executive Financial Services located at 1 New York Plaza, New York.
IDEXX Laboratories

NASDAQ:IDXX

IDXX Rankings

IDXX Latest News

IDXX Latest SEC Filings

IDXX Stock Data

54.95B
79.30M
0.68%
97.52%
2.56%
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
Link
United States
WESTBROOK